Table 4.
Baseline demographic and clinical characteristics: Subgroup analysis among switchers
| Characteristicsa | FTD + TPI‐to‐REG switchers (n = 96) | REG‐to‐FTD + TPI switchers (n = 83) | p valueb |
|---|---|---|---|
| Age at treatment initiation, mean ± SD (median) | 54.9 ± 9.0 (55) | 54.0 ± 7.8 (55) | .680 |
| Female, n (%) | 40 (41.7) | 38 (45.8) | .580 |
| Year of treatment initiation, n (%) | |||
| 2015 | 15 (15.6) | 20 (24.1) | .154 |
| 2016 | 69 (71.9) | 59 (71.1) | .907 |
| 2017 | 12 (12.5) | 4 (4.8) | .072 |
| Region, n (%) | |||
| South | 32 (33.3) | 36 (43.4) | .168 |
| Midwest | 33 (34.4) | 26 (31.3) | .665 |
| Northeast | 17 (17.7) | 8 (9.6) | .120 |
| West | 14 (14.6) | 12 (14.5) | .981 |
| Unknown | 0 (0.0) | 1 (1.2) | .464 |
| Insurance plan at treatment initiation, n (%) | |||
| PPO | 75 (78.1) | 69 (83.1) | .400 |
| HMO | 13 (13.5) | 7 (8.4) | .279 |
| POS | 6 (6.3) | 6 (7.2) | .794 |
| Indemnity/traditional | 2 (2.1) | 1 (1.2) | >.999 |
| Quan‐ CCI,b mean ± SD (median) | 6.4 ± 1.2 (6) | 6.2 ± 1.5 (6) | .892 |
| Selected comorbidities,c n (%) | |||
| Hypertension | 25 (26.0) | 29 (34.9) | .196 |
| Venous thromboembolism | 4 (4.2) | 4 (4.8) | >.999 |
| Coronary artery disease | 1 (1.0) | 1 (1.2) | >.999 |
| Other ischemic heart disease | 1 (1.0) | 1 (1.2) | >.999 |
| Cardiac dysrhythmia | 0 (0.0) | 2 (2.4) | .214 |
| Congestive heart failure | 1 (1.0) | 0 (0.0) | >.999 |
| Arterial thromboembolism | 0 (0.0) | 0 (0.0) | |
| Acute myocardial infarction | 0 (0.0) | 0 (0.0) | |
| Stroke | 0 (0.0) | 0 (0.0) | |
| mCRC antineoplastic therapy use,c n (%) | |||
| 5‐fluorouracil | 48 (50.0) | 44 (53.0) | .688 |
| Irinotecan | 50 (52.1) | 42 (50.6) | .843 |
| Bevacizumab | 44 (45.8) | 37 (44.6) | .866 |
| Leucovorin | 36 (37.5) | 30 (36.1) | .851 |
| Oxaliplatin | 17 (17.7) | 17 (20.5) | .637 |
| Cetuximab | 15 (15.6) | 8 (9.6) | .233 |
| Capecitabine | 13 (13.5) | 14 (16.9) | .535 |
| Panitumumab | 4 (4.2) | 10 (12.0) | .050 |
| Ramucirumab | 3 (3.1) | 3 (3.6) | >.999 |
| Ziv‐aflibercept | 0 (0.0) | 0 (0.0) |
a
Evaluated at the index date.
b
Chi‐square tests were used for categorical variables and Wilcoxon tests were used for continuous variables.
c
Evaluated during the 3‐month baseline period.
Abbreviations: FTD + TPI, trifluridine plus tipiracil; HMO, health maintenance organization; mCRC, metastatic colorectal cancer; POS, point of service; PPO, preferred provider organization; Quan‐CCI, Quan‐Charlson comorbidity index; REG, regorafenib; SD, standard deviation.